Almeida, FMacedo, ATrigo, DAbreu, MiguelGuimarães, MLuís, NPinho, RTavares, R2023-05-152023-05-152021Almeida F, Macedo A, Trigo D, et al. Neurocognitive evaluation using the International HIV Dementia Scale (IHDS) and Montreal Cognitive Assessment Test (MoCA) in an HIV-2 population. HIV Med. 2021;22(3):212-217. doi:10.1111/hiv.129631464-2662http://hdl.handle.net/10400.16/2776Objectives: We aimed to characterize neurocognitive impairment (NI) in an HIV-2 population using an observational cross-sectional study in four Portuguese hospitals. Methods: Adult HIV-2-infected patients were included. Montreal Cognitive Assessment Test (MoCA) and International HIV Dementia Scale (IHDS) scales were applied for screening of NI. Patient Health Questionnaire-9 (PHQ-9) and Instrumental Activities of Daily Living (IADL) scales were used for assessment of depression and functionality. A multivariate analysis was performed to assess for risk factors for NI. Results: Eighty-one patients were included, 50.6% of African origin (n = 41) and 49.4% of Portuguese origin (n = 40). The MoCA scale showed alterations in 81.5% of patients (100% of migrants vs. 62.5% of non-migrants, P < 0.001) and the IHDS scale showed alterations in 42%. Both scales were altered simultaneously in 35.8%. Variables independently associated with NI were age [odds ratio (OR) = 0.885] and migrant status (OR = 9.150). Conclusions: Neurocognitive impairment (both scales altered) was present in 35.8%, which is comparable to what is described for HIV-1. The MoCA performed worse in the migrant population and might not be applicable in this setting.engHIV-2HIV-associated neurocognitive disorderInternational HIV Dementia Scale (IHDS)Montreal Cognitive Assessment Test (MoCA)neurocognitive impairmentjournal article10.1111/hiv.12963